Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373539 · ClinicalTrials.gov registry record
Neurotrophin Expression in Infants as a Predictor of Respiratory and Neurodevelopmental Outcomes
A clinical trial, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 70
- Enrollment target
NCT03373539: Completed study, sponsored by The Cleveland Clinic.
NCT03373539 is a clinical trial that has completed, run by The Cleveland Clinic. The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03373539 has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 70 participants
- Enrollment target
Study Summary
Important developmental processes continue until the completion of 40 weeks gestation. Even during fetal life, intrinsic and environmental factors determine the balance between health and the onset and development of diseases. Thus, it is crucial to understand the mechanisms that regulate normal development and the pathways that contribute to disease pathogenesis. Neurotrophins are a family of four proteins that support the growth and survival of neurons. Their secretion increases during brain development, when new neurons are being formed and existing ones are branching to assemble complex neuronal circuits. In addition to their role in promoting neuron growth and development, neurotrophins are also a product of neuronal activity. Neurotrophins are also responsible for the maintenance of peripheral sensory neurons, including those in the lungs. Airway innervation is responsible for many aspects of lung function including the regulation of airway smooth muscle tone, mucus secretion, and reactivity; therefore, a physiological expression of neurotrophins in the lungs is required for normal lung function.
Primary Outcome
Neurotrophins include Nerve Growth Factor (NGF) and Brain-factor Neurotrophic Factor (BDNF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-12 |
| Est. Completion | 2019-08 |
What the finished NCT03373539 record still lists
NCT03373539 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03373539 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03373539 about?
NCT03373539 is a clinical study titled "Neurotrophin Expression in Infants as a Predictor of Respiratory and Neurodevelopmental Outcomes". Important developmental processes continue until the completion of 40 weeks gestation. Even during fetal life, intrinsic and environmental factors determine the balance between health and the onset and development of diseases. Thus, it is crucial to understand the mechanisms that regulate normal dev...
What is the current status of trial NCT03373539?
This trial is currently completed. The enrollment target is 70 participants. The study started on 2014-12. Estimated completion is 2019-08.
Who is sponsoring clinical trial NCT03373539?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia